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Abstract
Background: Recent studies suggest that humans exhale fine particles during tidal breathing but little is known of their
composition, particularly during infection.
Methodology/Principal Findings: We conducted a study of influenza infected patients to characterize influenza virus and
particle concentrations in their exhaled breath. Patients presenting with influenza-like-illness, confirmed influenza A or B
virus by rapid test, and onset within 3 days were recruited at three clinics in Hong Kong, China. We collected exhaled breath
from each subject onto Teflon filters and measured exhaled particle concentrations using an optical particle counter. Filters
were analyzed for influenza A and B viruses by quantitative polymerase chain reaction (qPCR). Twelve out of thirteen rapid
test positive patients provided exhaled breath filter samples (7 subjects infected with influenza B virus and 5 subjects
infected with influenza A virus). We detected influenza virus RNA in the exhaled breath of 4 (33%) subjects–three (60%) of
the five patients infected with influenza A virus and one (14%) of the seven infected with influenza B virus. Exhaled influenza
virus RNA generation rates ranged from ,3.2 to 20 influenza virus RNA particles per minute. Over 87% of particles exhaled
were under 1 mm in diameter.
Conclusions: These findings regarding influenza virus RNA suggest that influenza virus may be contained in fine particles
generated during tidal breathing, and add to the body of literature suggesting that fine particle aerosols may play a role in
influenza transmission.
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Introduction
Although the pathogen responsible for human influenza virus
infection was described over 70 years ago, ‘‘our understanding of
the transmission of influenza’’ has recently been characterized as
‘‘woefully inadequate’’ [1]. The US Department of Health and
Human Services Pandemic Influenza Preparedness Plan [2]
concluded that the relative importance for influenza transmission
of direct contact, large droplet, and airborne small particles is not
known. Two recent reviews in respected journals reached opposite
conclusions about how influenza is transmitted [3,4]. After
reviewing the same epidemiology, animal model, and case study
data, one review classified influenza as an opportunistically, and
only rarely, airborne transmitted disease while the other review
suggested that influenza is preferentially or obligatorily airborne
transmitted[5]. An Institute of Medicine report in 2007 stated that
the ‘‘paucity of definitive data on influenza transmission is a
critical gap in the knowledge base needed to develop and
implement effective prevention strategies’’[1].
Little is known about the aerosols produced by influenza-
infected subjects. In studies of exhaled breath particles from
healthy subjects during tidal breathing, researchers reported
concentrations from 1 to .10,000 particles per liter, with the
majority less than 0.3 mm in diameter [6–8]. One of these studies
also reported that 55% of the population studied exhaled.98% of
the particles and concluded that these subjects–classified as ‘‘high
producers’’–could over time exhale more particles during normal
tidal breathing than during relatively infrequent coughing or
sneezing events [8]. If particles exhaled during tidal breathing
contain infectious viruses, Edwards’ finding may have important
implications for airborne transmission of infectious diseases. In
animal models, influenza infection by airborne transmission has
been demonstrated in monkeys [9], ferrets [10–12], mice [13–20],
and guinea pigs [21,22]. Recent work by Huynh et al showed
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recovery of rhinovirus and parainfluenza virus via PCR from
infected patients who coughed and breathed through masks made
with electret [23]. Although they also studied subjects infected with
influenza virus, none was recovered.
To address gaps in our knowledge regarding the generation of
influenza virus aerosols, we report the concentration of influenza
virus RNA in the exhaled breath of persons infected with
influenza, and characterize their exhaled breath particle produc-
tion during tidal breathing.
Results
A total of 68 rapid flu tests were administered from July 23
through September 14, 2007: thirty-six were collected at Site A,
thirty at site B, and two from Site C. Over half (55%) of the
screened population was male, the average age was 35 years
(SD=12), the average body temperature was 38.1 (SD=0.7).
Only 9% of the screened subjects had been vaccinated for the
2007 season, and 8% reported having at least one influenza
vaccine in a previous influenza season. Thirty six of 68 subjects
given the rapid test completed the symptoms part of the
questionnaire and of these over 80% reported having cough,
headaches, fatigue, and sore throat.
Exhaled breath results
Thirteen (19%) of the subjects tested positive for influenza using
the rapid test and were asked to participate in the exhaled breath
study. According to the rapid test and confirmatory PCR, 5
subjects were infected with influenza A virus and 7 subjects were
infected with influenza B virus. Twelve of the 13 subjects provided
exhaled breath filter samples; one subject reported feeling too
fatigued and did not participate. Field blank filters were collected
from two uninfected individuals. Analysis of the flow-time record
supported the observation by field technicians that none of the
subjects coughed during filter collection.
We detected influenza virus RNA in the exhaled breath of 4
(33%) subjects: three (60%) of the five patients infected with
influenza A virus and one (14%) of the seven infected with
influenza B virus. There was no correlation between nasal and
throat swab influenza virus RNA concentrations and exhaled
breath influenza virus RNA concentrations. Table 1 presents the
demographic characteristics and symptoms of subjects, stratified
according to whether they had detectable influenza virus RNA in
their exhaled breath.
Concentrations in exhaled breath samples ranged from ,48 to
300 influenza virus RNA copies per filter on the positive samples,
corresponding to exhaled breath generation rates ranging from
,3.2 to 20 influenza virus RNA copies per minute. Table 2
presents the influenza virus type, viral RNA exhalation rate, and
viral RNA copies detected per well in each qPCR replicate from
the exhaled breath analysis of 12 tested subjects. All influenza A
virus samples were hemagglutinin type H3. Laboratory blanks and
the two field blanks collected were negative.
Particle counts
Exhaled breath particle size and number data was obtained for
10 of the 12 subjects who provided filter samples. Data from the
two remaining subjects, including the subject with the highest
concentration of exhaled influenza virus RNA, could not be
analyzed because of mask leaks. Across all subjects, total particle
Table 1. Demographic characteristics and symptoms of
subjects with and without detectable influenza virus RNA in
exhaled breath.
Exhaled breath
negative
Exhaled breath
positive
Total number 8 4
Male 75% 75%
Average age (years) (SD*) 37 (14) 34 (19)
Age range (years) 19–61 14–51
Body temperature (uC) (SD*) 38.3 (0.4) 38.7 (0.6)
Symptom onset
1–2 days past 75% 50%
3–5 days past 25% 50%
Vaccinated this season 13% 0%
Symptoms
Cough 100% 75%
Sputum changes** 13% 25%
Fatigue 100% 100%
Malaise 63% 75%
Headache 100% 100%
Sore throat 100% 75%
Diarrhea 0% 0%
Dyspnea 25% 25%
Chills 63% 50%
Sweats 63% 50%
*SD= standard deviation
**Increase in production or changes in character (color, consistency)
doi:10.1371/journal.pone.0002691.t001
Table 2. Influenza virus type, results for each qPCR replicate,
and exhalation rate.
qPCR of Filter Extracta
Subject ID
Influenza
virus type
(sub-type)
Replicate
1
Replicate
2
Replicate
3
Influenza
virus RNA
exhalation
rateb
A-06 A (H3) 47 21 44 20
A-07 A (H3) ND ND ,6 ,3.2
A-08 B ND ND ND ND
A-11 B ND ND ND ND
A-21 A (H3) ND ND ND ND
A-23 A (H3) ND ND ,6 ,3.2
A-24 B ND 7 ND ,3.2
A-25 B ND ND ND ND
A-34 B ND ND ND ND
B-01 A (H3) ND ND ND ND
B-09 B ND ND ND ND
B-25 B ND ND ND ND
A-37 (control) ND ND ND ND
A-38 (control) ND ND ND ND
aNumber of influenza RNA copies detected per well (5 ml cDNA per well).
bInfluenza virus RNA copies/ minute
ND=not detected by qPCR; limit of quantification was 6 influenza virus RNA
copies per qPCR well when all three replicates were detected.
doi:10.1371/journal.pone.0002691.t002
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concentrations ranged from 67 to 8,500 particles per liter of air.
Particle concentrations in the size selective bins ranged from 61 to
3,848 L21 (particles between 0.3 mm and ,0.5 mm), 5 to 2,756
L21 (0.5 mm and,1 mm), 1 to 1,916 L21 (1 mm and,5 mm), and
0 to 9 L21 ($5 mm). Figure 1 presents the averaged size
distribution of the particles measured from all 10 subjects. On
average 70% of the particles measured were between 0.3 mm and
,0.5 mm, 17% between 0.5 mm and ,1 mm, and 13% between
1 mm and ,5 mm. Particles larger than 5 mm were rarely
recorded (,0.1%). Of the 10 subjects, 50% exhaled more than
500 particles per liter of air. Two control samples were collected
from asymptomatic subjects who were not infected with influenza.
Both controls exhaled more than 500 particles per liter of air.
Discussion
We detected influenza virus RNA in the exhaled breath of 33%
of subjects with laboratory-confirmed influenza. Few previous
studies have examined microorganisms in exhaled breath: Couch
et al. published two reports of finding infectious Coxsackievirus in
large droplets and droplet nuclei generated by coughs and sneezes
[24–26]; Fennelly et al. recovered Mycobacterium tuberculosis from
infected patients who coughed into a collection box [27]; Downie
et al recovered infectious variola virus from smallpox patients who
talked next to an impinger [28]; Duguid et al. recovered indicator
oral bacteria from healthy subjects during nasal breathing, talking,
coughing, and sneezing, but none were recovered during mouth
breathing [29]. More recently Huynh et al looked for rhinovirus,
parainfluenza and influenza viruses from infected subjects who
breathed, talked and coughed through electret [23]. Via PCR they
were able to recover rhinovirus RNA and parainfluenza virus
RNA from coughing and talking maneuvers, and rhinovirus RNA
from tidal breaths; no influenza virus RNA was recovered. To the
best of our knowledge, previous exhaled breath studies have not
reported detection of influenza virus RNA aerosols during tidal
breathing.
Rudnick and Milton [30] used data from the influenza outbreak
aboard an aircraft reported by Moser et al [31] and the Wells-
Riley equation for non-steady-state conditions [32] to estimate a
quantum generation rate of from 79 to 128 quanta per hour for a
highly infectious influenza case. In this equation a quantum is the
infectious dose needed to initiate disease in 63% of exposed
subjects, is equivalent to an ID63, and can contain a number of
infectious viruses [33]. In the present study, we measured
generation rates of ,192 and 1200 influenza virus RNA copies
per hour for subjects with detectable influenza virus RNA in their
breath. Assuming each RNA copy represents one infectious virus,
and if, as Alford et al suggested [34,35], the human infectious dose
50% (ID50) by aerosol is between 0.6 and 3 TCID50, then one
quanta equals approximately one TCID50. This implies that the
quantum generation rate we measured in our subjects is 10-fold
higher than the Rudnick and Milton estimate for a ‘‘super-
spreader’’. However, not all viral RNA copies detected by PCR
are necessarily infectious. We found that our laboratory virus
stocks have a ratio of 300 virus particles per infectious virus
(characterized using real-time PCR and a cell culture-based
infectivity assay, data not shown)–a ratio consistent with reports
from other laboratories [36–38]. Thus the generation rate of
infectious viruses may be as little as 1/300th of the total number
determined by PCR and the resulting estimates of quantum
generation rate (,0.64 to 4 quanta/h) from our data are lower
than those estimated for a superspreader by Rudnick and Milton.
However, estimates based on tissue culture virus to RNA ratios
may be overly conservative because clinical specimens and
aerosols may have fewer defective viruses and less viral nucleic
acid which is not associated with virus particles.
Possible explanations for not detecting influenza virus RNA in a
larger proportion of subjects may be due to short sample collection
times, the large heterogeneity in the virus production among
infected patients (between 102 and 107 TCID50/ml of nasopha-
ryngeal fluid on the 2nd day following infection [39]), and the
detection limit for our qPCR method. The qPCR method can
quantify as few as 6 influenza virus RNA copies per qPCR well,
corresponding to 48 influenza virus RNA copies per filter or an
exhaled breath generation rate of 3.2 influenza virus RNA copies
per minute for a 15 minute sample. For the PCR to be considered
quantifiable in our study, all three sample replicates had to cross
the fluorescence signal threshold. Samples for which only one or
two of the replicates crossed the threshold were considered positive
but not quantifiable, and labeled ,3.2 influenza virus RNA
Figure 1. Exhaled breath particle size distribution averaged from 10 influenza infected subjects.
doi:10.1371/journal.pone.0002691.g001
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copies/min (Table 2). With this criterion only one subject had a
quantifiable generation rate of 20 influenza virus RNA copies/
min, three generated less than 3.2 influenza virus RNA copies/
min and the remaining either didn’t exhale influenza virus
aerosols, or generated undetectable numbers of influenza virus
RNA copies/min.
Influenza-infected subjects exhaled from 67 to 8,500 particles
per liter of air (geometric mean= 724); 50% of subjects exhaled
more than 500 particles per liter, a suggested threshold for
identification of high particle producers [8]. These results are
consistent with a previous study that measured particle concen-
trations of 14 to 3,230 particles per liter and also reported 54%
high particle producers among healthy adults using similar optical
counting methods [8]. Other studies of exhaled breath reported
particle concentrations of 20 and 400 particles per liter [40], or a
geometric mean of 230 particles per liter [6]. The numbers of
subjects in the published exhaled breath studies to date have all
been less than eleven. Larger studies of exhaled breath particle
concentrations are needed to better characterize the population
distribution of particle generation rates. Our study also had a small
number of subjects, and we do not have enough information to
suggest a relationship between particle production and the
probability of influenza virus RNA detection.
Although we don’t know whether the RNA we detected
originated from free nucleic acid, infectious, or non-infectious
viruses, the data presented here show that aerosols of influenza
virus origin are generated during tidal breathing. Our sampling
protocol required subjects to tidal breathe and patients did not
cough during sample collection. The data also suggest that
influenza virus RNA is contained in fine particles because over
87% of the exhaled particles were under 1 mm and less than 0.1%
were larger than 5 mm. This distribution of particle sizes is
consistent with previous studies showing that 98% of particles
produced during normal breathing are under 1 mm [6–8]. Thus,
based on the particle size distribution, it is unlikely that the viral
RNA detected was carried on large particles. We also note that the
Exhalair sampler fitted with a face mask as the patient interface
would likely impact most large particles (.20 mm) on the mask or
in tubing connecting the mask to the particle counter and filter
cassette. Therefore, it is likely that the influenza virus RNA we
detected in exhaled breath was contained in exhaled breath
particles ,5.0 mm in diameter. If influenza virus is carried in the
smaller particles and transmission occurs via the airborne route,
the use of interventions such as surgical-type masks as personal
protective equipment may not prevent transmission. However,
larger studies should be conducted to provide baseline data on
particle and infectious influenza virus generation, as well as
potential changes in virus generation due to use of surgical masks
by patients or healthcare professionals.
In order to study infectious viruses we need an efficient viral
aerosol sampler. Most bioaerosol samplers are not suitable for
recovering infectious viruses from exhaled breath due to short
period collection times, low flow rates, or collection substrates
which adversely affect virus infectivity. Other sampler limitations
include losses due to particle bounce, as is the case with many
impaction type particle collectors, and loss of collection media over
time, as is the case with liquid impingers. A new sampler should
combine efficient capture of small particles with liquid collection
media. Larger similar studies to the one reported in this
manuscript are needed to obtain information on particle
generation, infectious and non-infectious virus concentrations in
exhaled breath in order to estimate influenza virus quantum
generation rates, generation variability, and relationship to host
and virus characteristics.
Conclusions
The relative importance of various modes of influenza
transmission continue to be debated [3,4]. We detected influenza
virus RNA in the exhaled breath of 4 out of 12 influenza patients
and found that .99% of exhaled particles were ,5.0 mm in
diameter. These findings regarding influenza virus RNA suggest
that influenza virus may be contained in fine particles generated
during tidal breathing, and add to the body of literature suggesting
that fine particle aerosols may play a role in influenza
transmission.
Materials and Methods
Location and recruitment
This study was conducted on a subset of subjects recruited in a
randomized trial looking at the efficacy of face masks and hand
hygiene to reduce influenza transmission in Hong Kong residents
[41]. We recruited participants at three sites in Hong Kong, China
during July through September of 2007. Subjects 12 years of age
and older who presented with influenza-like illness (ILI) and were
within the first 3 days of onset of symptoms were invited to
participate in the study. A short questionnaire was used to record
age, gender, clinical illness symptoms, medication use, medical and
smoking history. Influenza-like-illness was defined as having a fever
$37.8uC and two or more ILI symptoms (fever, cough, sore throat,
runny nose, headache, malaise). Once written informed consent was
obtained, nasal and throat swabs were collected and analyzed using
a QuickVue Influenza A/B diagnostic test (Quidel Corp., San
Diego, CA) to confirm influenza virus infection. A second set of
nasal and throat swabs was collected and placed in viral transport
media buffer (Earl’s Balanced Salt Solution, 0.1% glucose, 0.5%
bovine albumin and antibiotic) refrigerated at 2–8uC immediately
after collection, stored at220uC for up to 7 days, and then stored at
280uC until analyzed for laboratory confirmation of influenza virus
infection by PCR. Only subjects who were determined to be
infected with influenza A or B virus according to the rapid
diagnostic test were asked to complete the exhaled breath collection.
The institutional review boards of The University of Hong Kong
and University of Massachusetts Lowell approved the research
protocols. Subjects were compensated for their time and the
inconvenience associated with participating in the study.
Particle count and collection system
We collected exhaled breath from subjects using an Exhalair
(Pulmatrix, Lexington, MA) a device which integrates optical
particle counting technology (Airnet 310, Particle Measuring
Systems, Boulder, CO) with airflow data obtained with a mass flow
meter and also collects filter samples. Subjects breathed with a
normal tidal pattern into an oro-nasal facemask (Hans Rudolph,
Shawnee, KS) for approximately 20 minutes total. The face piece
was connected to a respiratory T-valve which was equipped with a
HEPA filter on the intake side to supply particle free, make-up air
at very low resistance. A mass flow meter monitored inhalation
and exhalation flows and the instrument computed and stored
total and per breath flow and volume information. The outflow
side of the T-valve was connected via tubing to first the optical
particle counter and then to the filter sample collection part of the
Exhalair device. The optical particle counter recorded particle
counts in four size bins: 0.3 mm-,0.5, 0.5-,1 mm, 1-,5 mm and
$5 mm. A vacuum pump pulled air through the tubing at 28.3
lpm into a real-time particle counting system during the exhaled
breath particle characterization phase of the test (approximately
5 minutes). After completion of the particle counts, the outflow of
the T-valve was attached to a 37-mm, 2-mm pore-size Teflon filter
Influenza Virus in Breath
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with a polymethylpentene (PMP) support ring (Pall Life Sciences,
New York) and the vacuum pump was switched to pull through
the filter during the particle collection phase of the test
(15 minutes). Teflon filters were refrigerated at 2–8uC immediately
after collection, stored at 220uC for up to 7 days, and then stored
at 280uC until analyzed. T-valves and HEPA filters were disposed
of after each use and masks were disinfected using 10% bleach and
autoclaved prior to reuse.
RNA extraction from exhaled breath samples
Influenza virus RNA collected from the exhaled breath on the
Teflon filters was extracted using a Trizol-chloroform based method
modified from a protocol developed for extraction of nasal swab and
lavage samples [42]. Initially, the PMP support ring surrounding the
Teflon filter was cut 6 to 8 times around the circumference of the
filter and the filter was put into a 50-ml polypropylene centrifuge
tube containing 400 ml of phosphate buffered saline (PBS). A 10 ml
mixture containing 20 mg glycogen (Ambion, Austin, TX), 15 mg
glycoblue (Ambion, Austin, TX), 50 ng of Human DNA (BD
Biosciences, San Jose, CA) in PBS was added directly to each
sample. Next, 750 ml of Trizol LS (Invitrogen, Carlsbad, CA) was
added, the sample vortexed for 30 seconds and the liquid transferred
to a 1.7 ml low protein binding tube (LoBind, Eppendorf,
Westbury, NY). The tubes were placed on an MS2 Minshaker
(IKA works, Guangzhou, China) for 10 minutes at 300 rpm. After
mixing, 230 ml of chloroform (Sigma-Aldrich, St. Louis, MO) was
added and samples were briefly vortexed and placed on the shaker
at 300 rpm an additional 5 minutes. Samples were then centrifuged
at 21006g for 5 minutes and 700 ml of the aqueous supernatant was
transferred to a tube containing 600 ml of 100% isopropanol
(Sigma-Aldrich, St. Louis, MO) for RNA precipitation. After
incubating for1 hour at room temperature, RNA was pelleted by
centrifuging for 12 minutes at 200006g at room temperature. The
supernatant was decanted and 600 ml of 75% ethanol were added to
wash the pellets. The RNA pellets were centrifuged for 5 minutes at
200006g, the ethanol decanted and the pellets air dried for
approximately 20 minutes. The RNA was suspended in 20 ml of
nuclease-free water (Promega, Fitchburg, WI) and immediately
converted to cDNA.
RNA extraction from nasal swabs
RNA in the nasal and throat swabs was extracted from 140 ml of
viral transport media using Qiagen QIAamp Viral RNA mini
columns (Qiagen Corp., Valencia, CA) in accordance with the
manufacturer instructions. The RNA was eluted in 100 ml of
carrier buffer and immediately converted to cDNA. Unused RNA
was stored at 280uC.
Reverse transcription
cDNA was synthesized from purified and concentrated RNA
using a High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). A 20 ml total reaction volume was
made with 10 ml RNA, 2 ml 10X RT buffer, 0.8 ml dNTP Mix
(100 mM), 2.0 ml 10X RT random hexamer primers, 1.0 ml
MultiScribeTM reverse transcriptase, 1 ml RNase inhibitor and
3.2 ml nuclease-free water. Synthesis was carried out in an ABI 9700
Thermocycler (Applied Biosystems, Foster City, CA) and reaction
conditions were 25uC for 10 minutes, 37uC for 120 minutes, and
85uC for 5 seconds. cDNA samples were stored at 220uC.
Quantitative PCR
Quantitative PCR was performed using an Applied Biosystems
Prism 7500 detection system (Foster City, CA). Triplicate cDNA
samples were analyzed in a 96-well plate with an adhesive film
cover (Applied Biosystems, Foster City, CA). Each well contained
5 ml of cDNA template, 12.5 ml of 2X TaqmanTM Universal PCR
Master Mix (Applied Biosystems, Foster City, CA), 900 nM of
each primer and 100 nM probe.
We tested three primer/probe sets on 17 nasal swab samples
collected for this project in order to select the most sensitive for the
exhaled breath and remaining nasal swab samples: a set used by
the Centers for Disease Control, a set used at the Queen Mary
Hospital Virology laboratory (QMH) and a set from the published
literature [38]. Based on the sensitivity results from these tests the
following set of primers and probe were selected to analyze the
exhaled breath samples: for influenza A virus two forward primers
59- GGA CTG CAG CGT AGA CGC TT-39 and 59- CAT CCT
GTT GTA TAT GAG GCC CAT-39, reverse primer 59- CAT
TCT GTT GTA TAT GAG GCC CAT- 39, and probe 59FAM-
CTC AGT TAT TCT GCT GGT GCA CTT GCC A -
39TAMRA; for influenza B virus forward primer 59- AAA TAC
GGT GGA TTA AAT AAA AGC AA-39, reverse primer 59-
CCA GCA ATA GCT CCG AAG AAA -39, and probe 59FAM
CAC CCA TAT TGG GCA ATT TCC TAT GGC -39TAMRA
[38]. The primers and probe targeted the matrix (M) gene and the
hemagglutinin (HA) gene for influenza A and B viruses
respectively. Primers and probe were manufactured by Sigma-
Proligo (Proligo Singapore Pty Ltd).
We constructed standard curves for the qPCR by making 1:10
dilutions of cDNA made from QMH influenza A and B virus
stocks. Influenza A/PR/8/34 and influenza B/Hong Kong/
AE34/2002 virus stocks were grown at QMH on MDCK cells and
purified via a sucrose density gradient. Once purified, 50 ml
aliquots of each virus were extracted using the Trizol-chloroform
method described previously, synthesized to cDNA using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA) and quantified by qPCR with a plasmid standard
curve for each influenza virus. The virus concentrations calculated
based on this method were 1.886107 and 1.666106 virus particles
per ml for the influenza A and B virus stocks, respectively. The
limit of quantification for the qPCR was 6 influenza A or B viral
RNA particles per PCR well, with all three replicates crossing the
qPCR fluorescence threshold within 37 cycles. For the exhaled
breath filters and nasal swabs, samples were considered positive if
at least one of the three replicates crossed the qPCR cycle
threshold, but were only quantifiable if all three replicates crossed
the cycle threshold. Because 25% of the cDNA was used per well
and 50% of the extracted RNA was used to make cDNA, the total
number of virus copies per filter was 8 times the average copy
number per well.
Influenza virus sub-typing
The RNA from the nasal swab samples positive for influenza A
virus were shipped to the Centers for Disease Control Virus
Surveillance and Diagnostics Branch Influenza Division. Samples
were tested for H1 and H3 sub-types using quantitative PCR
methods.
Data analysis
Exhaled virus concentrations in exhaled breath were computed
from the qPCR results and the Exhalair record of total exhaled
volume during filter sample collection. Total particle concentra-
tions and concentrations in each size bin were calculated for each
breath by dividing the number of particles counted by the volume
exhaled. We then averaged the particle concentrations over all
breaths collected for each subject. Computations were performed
in SAS for Windows (version 9.1.3, Cary, NC).
Influenza Virus in Breath
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